Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Communities across New York — from Adams to smaller towns — are now accessing FDA-approved GLP-1 medications through licensed telehealth providers without leaving home. Your neighbors are getting results; you can too. Our NY-licensed physician network evaluates eligibility and prescribes the right GLP-1 medication for your community and your needs.
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed weight management for communities nationwide, with clinical trials showing 15-22% average body weight reduction. These same results are now available to every New York community through telehealth.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
New York supports telehealth prescribing rights that allow licensed physicians to serve patients in every corner of the state — urban and rural alike. All NY-licensed providers in our network understand the local community healthcare landscape and comply with all applicable state and federal regulations.
Find your community below and connect with a local licensed GLP-1 provider. Every New York community has access.
The clinical evidence for FDA-approved GLP-1 receptor agonists comes from large phase III randomized controlled trials published in the New England Journal of Medicine:
New York authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in New York.
Our telehealth network connects communities across New York and its neighboring states — providing access wherever you live.
Board-certified physicians offer GLP-1 telehealth consultations in every city across the state. Choose your city below for localized service information and eligibility details.
Local weight loss and GLP-1 providers serving the New York area, based on Google Business listings.
120 E 56th St %231040, New York, NY 10022
(212) 759-8118
4.8/5 ★ (33 reviews)
Visit website →10 Barclay St, New York, NY 10007
5/5 ★ (34 reviews)
Visit website →245 5th Ave 3rd floor suite 306, New York, NY 10016
(917) 408-6103
4.9/5 ★ (129 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes, in every community across New York — from the largest cities to small towns. Our network of NY-licensed telehealth physicians provides GLP-1 prescribing access to all residents, regardless of where they live in the state.
Every New York community can access the full range of FDA-approved GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — through telehealth, the same medications available at specialist clinics in large cities.
Medication delivery through licensed US pharmacies reaches every New York address — urban or rural. After consultation and prescription approval, your GLP-1 medication typically ships within 24-48 hours and arrives within 3-5 business days, no matter where in New York you live.
All physicians in our network hold active NY medical licenses and are familiar with New York healthcare regulations, local coverage options, and community health needs. They prescribe within full compliance of all applicable state laws and regulations.
Yes. GLP-1 telehealth has grown rapidly across New York communities. Patients in large cities and small towns alike are achieving 15-22% average body weight reduction through online consultations and home delivery. The community is already embracing this accessible approach to weight management.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
